Page 36 - Read Online

Conroy et al. Cancer Drug Resist 2021;4:543-58 https://dx.doi.org/10.20517/cdr.2021.07 Page 13

Availability of data and materials
Not applicable.

Financial support and sponsorship
Funding source: Work in Walter Kolch’s lab is funded by Science Foundation Ireland (SFI) under Grant
Numbers 18/SPP/3522 and 14/IA/2395.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Harvey JJ. An unidentified virus which causes the rapid production of tumours in mice. Nature 1964;204:1104-5. DOI PubMed
2. Kirsten WH, Mayer LA. Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst 1967;39:311-35. PubMed
3. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
Science 2008;321:1801-6. DOI PubMed PMC
4. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov
2014;13:828-51. DOI PubMed PMC
5. Kwong LN, Davies MA. Targeted therapy for melanoma: rational combinatorial approaches. Oncogene 2014;33:1-9. DOI PubMed
6. Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2014;142:164-75. DOI
PubMed
7. Cromm PM, Spiegel J, Grossmann TN, Waldmann H. Direct Modulation of Small GTPase Activity and Function. Angew Chem Int Ed
Engl 2015;54:13516-37. DOI PubMed
8. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-31. DOI PubMed PMC
9. Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE 2004;2004:RE13. DOI PubMed PMC
10. Weinberg RA. The biology of cancer. 2nd ed. New York, NY: Garland Science; 2014.
11. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11:761-74. DOI
PubMed PMC
12. Coelho MA, de Carné Trécesson S, Rana S, et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1
mRNA. Immunity 2017;47:1083-1099.e6. DOI PubMed PMC
13. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and
developmental defects. Cancer Cell 2004;5:375-87. DOI PubMed
14. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.
Cancer Cell 2003;4:111-20. DOI PubMed
15. Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: Roles in precision medicine. Semin Cancer Biol 2019;59:23-
35. DOI PubMed
16. Mengoli MC, Barbieri F, Bertolini F, Tiseo M, Rossi G. K-RAS mutations indicating primary resistance to crizotinib in ALK-
rearranged adenocarcinomas of the lung: Report of two cases and review of the literature. Lung Cancer 2016;93:55-8. DOI PubMed
17. Martinelli E, Morgillo F, Troiani T, Ciardiello F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of
MEK. Cancer Treat Rev 2017;53:61-9. DOI PubMed
18. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung
adenocarcinoma. J Thorac Oncol 2008;3:111-6. DOI PubMed
19. Cadranel J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and
overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC
project--part 2). J Thorac Oncol 2012;7:1490-502. DOI PubMed
20. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011;11:775-91. DOI PubMed
PMC
21. Morgillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006;15:709-19. DOI PubMed